search
Back to results

Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant

Primary Purpose

Non-inflammatory Degenerative Joint Disease

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Total Hip Replacement
Sponsored by
Anderson Orthopaedic Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-inflammatory Degenerative Joint Disease focused on measuring total hip replacement, primary cementless total hip arthroplasty, metal ion, metal-on-metal

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Undergoing cementless primary total hip replacement
  • Receiving acetabular cup of 52mm or greater
  • Preoperative level of function and pain same as for conventional hip replacement
  • Likelihood of obtaining relief of pain and improved function
  • Full skeletal maturity
  • Ability to follow instructions
  • Good general health
  • Willing to return for follow-up evaluations
  • X-ray evaluation confirming the presence of NIDJD
  • Femoral and acetabular bone stock that is sufficient, regarding strength and shape, and suitable to receive the implants

Exclusion Criteria:

  • Age less than 40 years or greater than 80 years at time of surgery
  • Patients templated to receive an acetabular component smaller than 52mm in diameter
  • Presence of a previous prosthetic hip replacement device in the hip joint to be operated
  • Previous girdlestone procedure or surgical fusion of the hip to be operated
  • Acute femoral neck fracture
  • Above knee amputation of the contralateral and/or ipsilateral leg
  • Patients with a diagnosis of inflammatory degenerative arthritis
  • Skeletally immature
  • Evidence of active infections that may spread to other areas of the body
  • The presence of a highly communicable disease that may limit follow-up
  • Presence of known active metastatic or neoplastic disease
  • Significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weightbearing
  • Any previous hip surgery or conditions that may interfere with the total hip replacement's survival or outcome
  • Any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or indicates difficulty to return for follow-up
  • Patient is know to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser
  • Any patient who qualifies for inclusion in the study but refuses consent to participate in the study
  • Any steroid therapy, local or systemic, within three months prior to surgery
  • Patient requiring structural bone grafts in order to support the prosthetic components or to shape the bone to receive the implants
  • Patient has known allergies to metal, e.g., jewelry
  • Any patient not meeting all radiographic and clinical parameters for inclusion

Sites / Locations

  • Anderson Orthopaedic Research Institute
  • Department of Orthopaedic Surgery, University of Western Ontario

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Metal-on-Polyethylene

Metal-on-Metal, 28mm femoral head

Metal-on-Metal, 36mm femoral head

Arm Description

Outcomes

Primary Outcome Measures

cobalt, chromium, and titanium ion levels in blood and urine

Secondary Outcome Measures

Hip function
Durability

Full Information

First Posted
August 19, 2009
Last Updated
August 14, 2015
Sponsor
Anderson Orthopaedic Research Institute
Collaborators
University of Western Ontario, Canada, DePuy Orthopaedics
search

1. Study Identification

Unique Protocol Identification Number
NCT00962351
Brief Title
Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant
Official Title
Metal Ion Release From an FDA Approved Metal-on-Metal Hip Replacement Implant: A Multi-Center, Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
October 2003 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Anderson Orthopaedic Research Institute
Collaborators
University of Western Ontario, Canada, DePuy Orthopaedics

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multi-center, randomized study to compare blood and urine cobalt, chromium, and titanium ion levels of a metal-on-metal articular bearing coupled with two different head sizes to that of a conventional metal-on-polyethylene bearing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-inflammatory Degenerative Joint Disease
Keywords
total hip replacement, primary cementless total hip arthroplasty, metal ion, metal-on-metal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metal-on-Polyethylene
Arm Type
Other
Arm Title
Metal-on-Metal, 28mm femoral head
Arm Type
Other
Arm Title
Metal-on-Metal, 36mm femoral head
Arm Type
Other
Intervention Type
Procedure
Intervention Name(s)
Total Hip Replacement
Primary Outcome Measure Information:
Title
cobalt, chromium, and titanium ion levels in blood and urine
Time Frame
Pre-op, 6 months, 1 year, 2 years, 3 years, 5 years
Secondary Outcome Measure Information:
Title
Hip function
Time Frame
Pre-op, 6 months,1 year, 2 years, 3 years, 5 years
Title
Durability
Time Frame
6 months, 1 year, 2 years, 3 years, 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Undergoing cementless primary total hip replacement Receiving acetabular cup of 52mm or greater Preoperative level of function and pain same as for conventional hip replacement Likelihood of obtaining relief of pain and improved function Full skeletal maturity Ability to follow instructions Good general health Willing to return for follow-up evaluations X-ray evaluation confirming the presence of NIDJD Femoral and acetabular bone stock that is sufficient, regarding strength and shape, and suitable to receive the implants Exclusion Criteria: Age less than 40 years or greater than 80 years at time of surgery Patients templated to receive an acetabular component smaller than 52mm in diameter Presence of a previous prosthetic hip replacement device in the hip joint to be operated Previous girdlestone procedure or surgical fusion of the hip to be operated Acute femoral neck fracture Above knee amputation of the contralateral and/or ipsilateral leg Patients with a diagnosis of inflammatory degenerative arthritis Skeletally immature Evidence of active infections that may spread to other areas of the body The presence of a highly communicable disease that may limit follow-up Presence of known active metastatic or neoplastic disease Significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weightbearing Any previous hip surgery or conditions that may interfere with the total hip replacement's survival or outcome Any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or indicates difficulty to return for follow-up Patient is know to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser Any patient who qualifies for inclusion in the study but refuses consent to participate in the study Any steroid therapy, local or systemic, within three months prior to surgery Patient requiring structural bone grafts in order to support the prosthetic components or to shape the bone to receive the implants Patient has known allergies to metal, e.g., jewelry Any patient not meeting all radiographic and clinical parameters for inclusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
C. Anderson Engh, Jr., MD
Organizational Affiliation
Anderson Orthopaedic Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steven J. MacDonald, MD
Organizational Affiliation
Department of Orthopaedic Surgery, University of Western Ontario
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anderson Orthopaedic Research Institute
City
Alexandria
State/Province
Virginia
ZIP/Postal Code
22306
Country
United States
Facility Name
Department of Orthopaedic Surgery, University of Western Ontario
City
London
State/Province
Ontario
ZIP/Postal Code
N6A5A5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
18855089
Citation
Engh CA Jr, MacDonald SJ, Sritulanondha S, Thompson A, Naudie D, Engh CA. 2008 John Charnley award: metal ion levels after metal-on-metal total hip arthroplasty: a randomized trial. Clin Orthop Relat Res. 2009 Jan;467(1):101-11. doi: 10.1007/s11999-008-0540-9. Epub 2008 Oct 15.
Results Reference
result

Learn more about this trial

Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant

We'll reach out to this number within 24 hrs